ADAM12 Gene

📖 Wiki Page

gene1670 wordssynced 2026-04-02

ADAM12 Gene

Overview

...

ADAM12 Gene

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ADAM12 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>ADAM12</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>ADAM metallopeptidase domain 12</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>10q26.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>8030</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>602714</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000138744</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>O43827</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers-disease), Cancer, Muscular Dystrophy</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Stage</td>
</tr>
<tr>
<td class="label">ADAM12 neutralizing antibodies</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">ADAM12 siRNA therapeutics</td>
<td>Research</td>
</tr>
<tr>
<td class="label">ADAM12 promoter inhibitors</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Gene therapy vectors</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Domain</td>
<td>Function</td>
</tr>
<tr>
<td class="label">Prodomain</td>
<td>Enzyme latency, secretion</td>
</tr>
<tr>
<td class="label">Metalloprotease</td>
<td>Substrate cleavage</td>
</tr>
<tr>
<td class="label">Disintegrin</td>
<td>Cell adhesion</td>
</tr>
<tr>
<td class="label">Cysteine-rich</td>
<td>Protein interactions</td>
</tr>
<tr>
<td class="label">EGF-like</td>
<td>Receptor binding</td>
</tr>
<tr>
<td class="label">Transmembrane</td>
<td>Membrane anchoring</td>
</tr>
<tr>
<td class="label">Cytoplasmic tail</td>
<td>Signaling, localization</td>
</tr>
<tr>
<td class="label">Substrate</td>
<td>Cleavage Site</td>
</tr>
<tr>
<td class="label">IGF-1 binding protein</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">TGF-α</td>
<td>Ala²⁴⁴-Val²⁴⁵</td>
</tr>
<tr>
<td class="label">IL-6R</td>
<td>Arg³⁵⁹-Ser³⁶⁰</td>
</tr>
<tr>
<td class="label">Notch</td>
<td>Val¹⁷¹⁴-Leu¹⁷¹⁵</td>
</tr>
<tr>
<td class="label">HB-EGF</td>
<td>Leu¹⁴⁴-Val¹⁴⁵</td>
</tr>
<tr>
<td class="label">Vitronectin</td>
<td>Multiple</td>
</tr>
</table>

ADAM12 (A Disintegrin And Metalloproteinase domain 12) is a metalloproteinase involved in cell adhesion, differentiation, and muscle development. It is located on chromosome 10q26.3 and has been studied in the context of [Alzheimer's disease](/diseases/alzheimers-disease), cancer, and muscular disorders.

Gene Information

Protein Structure

ADAM12 shares the typical ADAM domain architecture:

Signal peptide: Directs protein to secretory pathway
Prodomain: Maintains enzyme latency; removed for activation
Metalloproteinase domain: Catalytic protease domain
Disintegrin domain: Mediates cell adhesion
Cysteine-rich region: Regulatory functions
EGF-like domain: Protein interactions
Transmembrane domain: Membrane anchoring
Cytoplasmic tail: Signaling and localization

Molecular Function

ADAM12 participates in multiple cellular processes[@blobel2015][@kveiborg2006]:

Proteolytic Processing

Cleaves growth factors (IGF-1, TGF-alpha)
Processes cytokines and adhesion molecules
Generates sheddases for membrane proteins

Cell Adhesion and Migration

Mediates cell-cell interactions via integrin binding
Facilitates epithelial-mesenchymal transition (EMT)
Regulates cell matrix interactions

Signaling Pathways

EGFR signaling: Releases EGF-like ligands
IGF-1 signaling: Modulates growth factor availability
Notch signaling: Participates in proteolytic cleavage

Expression Pattern

ADAM12 shows tissue-specific expression:

High expression: Skeletal muscle, heart, placenta
Moderate expression: Brain, lung, liver
Low expression: Most other tissues

In the brain, ADAM12 is expressed in [neurons](/entities/neurons) and glial cells, with altered expression in neurodegenerative conditions.

Disease Associations

Alzheimer's Disease

ADAM12 may contribute to [Alzheimer's disease](/diseases/alzheimers-disease) pathogenesis through multiple mechanisms[@tousseyn2017]:

APP processing: Potential involvement in [amyloid precursor protein](/entities/app-protein) cleavage
Synaptic dysfunction: Effects on synaptic plasticity
Neuronal survival: Role in anti-apoptotic signaling

Cancer

ADAM12 is frequently overexpressed in cancers:

Breast cancer: Promotes tumor growth and invasion
Pancreatic cancer: Associated with poor prognosis
Glioma: Correlates with malignancy grade

Muscular Disorders

ADAM12 is involved in muscle development and regeneration:

Duchenne muscular dystrophy: Elevated expression
Muscle injury: Upregulated during regeneration

Therapeutic Potential

ADAM12 is being explored as a therapeutic target:

Cancer therapy: Antibody-drug conjugates targeting ADAM12
Muscle disorders: Modulating regeneration pathways
Biomarker: Serum ADAM12 as cancer biomarker

ADAM12 in Alzheimer's Disease Pathogenesis

The Amyloid Precursor Protein Processing Pathway

The [amyloid precursor protein](/proteins/app-protein) (APP) is a transmembrane protein that undergoes proteolytic processing by three major secretases: alpha-, beta-, and gamma-secretases. ADAM12 has emerged as a significant non-canonical alpha-secretase with important implications for [Alzheimer's disease](/diseases/alzheimers-disease) pathogenesis[@tousseyn2017].

Alpha-Secretase Processing

ADAM12 processes APP within the amyloid-beta (Aβ) sequence, generating:

sAPPα (soluble APP alpha): A neuroprotective fragment that promotes neuronal survival, synaptic plasticity, and memory formation
CTFα (C-terminal fragment alpha): A membrane-retained fragment that can be further processed

This processing pathway is often termed the "non-amyloidogenic" pathway because it precludes formation of the Aβ peptide. ADAM12's activity therefore represents a potentially protective mechanism against amyloid deposition[@tousseyn2017].

Competition with Beta-Secretase

When ADAM12 activity is reduced:

More APP is available for beta-secretase (BACE1) processing
This leads to increased production of sAPPβ and CTFβ
CTFβ is subsequently processed by gamma-secretase to generate Aβ peptides
The shift toward amyloidogenic processing promotes plaque formation

Neuroprotective Effects of sAPPα

The sAPPα fragment generated by ADAM12 (and other alpha-secretases like ADAM9, ADAM10, and ADAM17) exerts multiple neuroprotective effects:

Synaptic plasticity: sAPPα enhances long-term potentiation (LTP) in the hippocampus, a cellular correlate of memory formation

Neuroprotection: sAPPα protects neurons against excitotoxicity, oxidative stress, and apoptotic cell death

Neurogenesis: Promotes neural progenitor cell proliferation in the subventricular zone and hippocampus

Blood-brain barrier: Supports BBB integrity and reduces neuroinflammation

Glucose metabolism: Improves neuronal glucose uptake and mitochondrial function

ADAM12 Expression in Alzheimer's Disease Brain

Studies have shown altered ADAM12 expression in AD brains:

Elevated ADAM12 in AD brain: Some studies report increased ADAM12 mRNA and protein in AD temporal cortex and hippocampus
Cellular localization: ADAM12 is expressed in neurons, astrocytes, and microglia, with highest expression in areas prone to amyloid deposition
Correlation with pathology: ADAM12 expression correlates with both Aβ plaque burden and neurofibrillary tangle density in some brain regions

Temporal Pattern

ADAM12 expression changes appear to follow a temporal pattern in AD progression:

Early AD: Increased ADAM12 may represent a compensatory neuroprotective response

Moderate AD: Expression may become dysregulated

Advanced AD: Potential downregulation in regions with significant neuronal loss

Mechanistic Links Between ADAM12 and AD Pathogenesis

Interaction with Presenilins

ADAM12 may interact with the gamma-secretase complex components (presenilin-1 and presenilin-2):

ADAM12 cleavage products may influence gamma-secretase activity
Competition between alpha- and gamma-secretase for substrate
Potential feedback mechanisms affecting amyloidogenesis

Effects on Tau Phosphorylation

Beyond amyloid processing, ADAM12 may influence tau pathology:

sAPPα generated by ADAM12 can modulate GSK-3β activity
Reduced alpha-secretase activity may lead to increased tau phosphorylation
ADAM12-mediated signaling affects multiple kinases involved in tau pathology

Neuroinflammation Modulation

ADAM12 plays a role in neuroinflammatory processes:

Regulates cytokine release from microglia and astrocytes
Influences blood-brain barrier permeability
Modulates astrocyte reactivity in response to Aβ

ADAM12 in Parkinson's Disease

While less studied than in Alzheimer's disease, ADAM12 has emerging relevance to [Parkinson's disease](/diseases/parkinsons-disease):

Alpha-Synuclein Processing

ADAM12 may participate in processing of [alpha-synuclein](/proteins/alpha-synuclein) or related proteins:

Potential cleavage of alpha-synuclein aggregates
Modulation of protein aggregation pathways
Effects on neuronal protein homeostasis

Dopaminergic Neuron Vulnerability

ADAM12 expression in dopaminergic neurons may influence their selective vulnerability:

Modulates neurotrophic factor signaling
Affects oxidative stress responses
May influence mitochondrial function

Clinical Trials and Therapeutic Applications

ADAM12-Targeted Therapies

ADAM12 as Biomarker

Serum and urine ADAM12 levels have been investigated as biomarkers:

Cancer diagnosis: Elevated ADAM12 in breast, ovarian, and pancreatic cancers
Prognostic value: Higher levels correlate with poor prognosis in some cancers
Monitoring: Potential for treatment response tracking

Research Directions and Knowledge Gaps

Key Unresolved Questions

ADAM12 isoform-specific functions: The functional significance of ADAM12-S (secreted) vs ADAM12-M (membrane-bound) isoforms in the brain

Cell type-specific regulation: How ADAM12 expression is regulated in different neural cell types

Therapeutic targeting: Whether enhancing or inhibiting ADAM12 would be more beneficial in AD

Biomarker validation: Large-scale studies needed to validate ADAM12 as a disease biomarker

Ongoing Research Areas

Small molecule activators: Screening for compounds that enhance ADAM12 alpha-secretase activity
Gene therapy approaches: AAV vectors expressing ADAM12 for neuroprotection
Combination therapies: ADAM12 activation combined with other anti-amyloid strategies
Biomarker development: Clinical validation of ADAM12 in cerebrospinal fluid

ADAM12 Structure-Function Relationships

Domain-Specific Roles

Post-Translational Modifications

ADAM12 undergoes several important post-translational modifications:

Prodomain cleavage: Required for enzymatic activation
glycosylation: Affects folding, stability, and secretion
Phosphorylation: Modulates signaling functions
Ubiquitination: Targets for degradation

Summary

ADAM12 is a multifunctional metalloproteinase with significant implications for neurodegenerative disease research. Its role as an alpha-secretase positions it as a potentially protective enzyme in Alzheimer's disease by promoting non-amyloidogenic APP processing. The resulting sAPPα fragment exerts neuroprotective effects on synaptic plasticity, neuronal survival, and neuroinflammation.

Understanding the regulation of ADAM12 expression and activity in the brain, and developing therapeutic strategies to modulate its function, represents a promising approach to neurodegenerative disease intervention.

Structural Biology of ADAM12

Crystal Structure Insights

The metalloproteinase domain of ADAM12 adopts the typical metzincin fold:

Active site: HEXGHNLGxxHDED motif coordinates zinc ion
S1 pocket: Determines substrate specificity
Disintegrin loop: Mediates cell adhesion interactions
Cysteine switch: Regulates prodomain removal

Substrate Specificity

ADAM12 cleaves numerous substrates beyond APP:

ADAM12 in Other Neurodegenerative Disorders

Huntington's Disease

Emerging evidence suggests ADAM12 involvement:

Altered expression in HD brain
Potential role in mutant huntingtin processing
Effects on neurotrophic factor signaling
Modulation of striatal neuron vulnerability

Multiple Sclerosis

ADAM12 may contribute to demyelination:

Upregulated in demyelinating lesions
Effects on oligodendrocyte function
Blood-brain barrier disruption
Inflammatory mediator release

Research Methodology

Detecting ADAM12 Activity

Western blotting: Detect pro and active forms
ELISA: Quantify sAPPα release
Activity assays: Fluorogenic substrate cleavage
Immunohistochemistry: Tissue localization
qPCR: mRNA expression analysis

Key Publications

[ADAM12 in disease (2015)](https://pubmed.ncbi.nlm.nih.gov/26069251/)

[ADAM12 and Alzheimer's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28632489/)

[ADAM12 in cancer progression (2019)](https://pubmed.ncbi.nlm.nih.gov/31154234/)

External Links

[NCBI Gene: adam12](https://www.ncbi.nlm.nih.gov/gene/)
[PubMed: adam12](https://pubmed.ncbi.nlm.nih.gov/?term=adam12+neurodegeneration)

Brain Atlas Resources

[Allen Human Brain Atlas](https://human.brain-map.org/) — gene expression data](/datasets/allen-human-brain-atlas)
[BrainSpan Atlas](https://brainspan.org/) — developmental transcriptome](/datasets/brainspan-atlas)
[Allen Mouse Brain Atlas](https://mouse.brain-map.org/) — mouse brain gene expression

Mechanism Map

Mermaid diagram (expand to render)

References

[Blobel CP, ADAMs: key players in EGFR signaling and development (2015)](https://doi.org/10.1016/j.yexcr.2015.02.012)

[Tousseyn T, Thathiah A, Czirr E, et al, ADAM12 is a novel alpha-secretase generating amyloidogenic fragments of the amyloid precursor protein (2017)](https://pubmed.ncbi.nlm.nih.gov/28632489/)

[Kveiborg M, Albrechtsen R, Couchman JR, Wewer UM, Cellular roles of ADAM12 in pathology and physiology (2006)](https://pubmed.ncbi.nlm.nih.gov/16430879/)

📖 View canonical wiki page →